Telix has announced that the first patient has been dosed in an early access program in the Netherlands for its investigational positron emission tomography imaging agent TLX250-CDx in clear cell renal cell carcinoma. …
Telix says the first patient dosed in European early access program for TLX250-CDx
December 6, 2023 Australian Biotech
Latest Video
New Stories
-
Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer
October 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 October
October 17, 2025 - - Podcast -
New partnership aims to strengthen local cell and gene manufacturing capability
October 16, 2025 - - Australian Biotech -
Vertex announces New Zealand registration of next-generation cystic fibrosis treatment
October 16, 2025 - - Latest News -
Lilly’s oral GLP-1 therapy delivers strong results in late-stage diabetes trials
October 16, 2025 - - Latest News -
NDIS participant numbers and spending continue growth trajectory in latest quarterly data
October 15, 2025 - - Other Health -
Key Pharmaceuticals builds on a 40-year legacy to support frontline health
October 15, 2025 - - Latest News